Individuals with the GSTT1-null genotype have been shown to be at a increased risk for developing MDS [22], and polymorphisms in GSTM1 and GSTP are associated with a higher risk of developing CLL [29]. This evidence concerns the gene GSTM1 and myelodysplastic syndrome.